Goldman Sachs’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Goldman Sachs’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-360,000	Closed	-$115K	–	6253
2018 Q1	$115K	Buy	+360,000	New	+$538K	﹤0.01%	5231
2016 Q1	–	Sell	-25,000	Closed	-$928K	–	7476
2015 Q4	$928K	Sell	25,000 -138	-0.5%	-$6.09K	﹤0.01%	4377
2015 Q3	$1.23M	Buy	25,138 +23,938	+1,995%	+$1.67M	﹤0.01%	4276
2015 Q2	$83K	Buy	1,200 +1,012	+538%	+$46.8K	﹤0.01%	6699
2015 Q1	$7K	Buy	+188	New	+$5.56K	﹤0.01%	6994

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Goldman Sachs's ANTH Position: Q2 2018 in Review

Goldman Sachs sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 115,801 shares — an estimated $37K sold.

Goldman Sachs first reported a position in ANTH in Q4 2014 and held it in 12 quarters. The position peaked at $576K in Q4 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Goldman Sachs reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Goldman Sachs sold 115,801 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $37K.
Goldman Sachs first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
Goldman Sachs's Anthera Pharmaceuticals, Inc. position peaked at $576K in Q4 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.